216 related articles for article (PubMed ID: 33389482)
1. DNA double-strand breaks repair inhibitors potentiates the combined effect of VP-16 and CDDP in human colorectal adenocarcinoma (LoVo) cells.
Kopa P; Macieja A; Pastwa E; Majsterek I; Poplawski T
Mol Biol Rep; 2021 Jan; 48(1):709-720. PubMed ID: 33389482
[TBL] [Abstract][Full Text] [Related]
2. SCR7 is neither a selective nor a potent inhibitor of human DNA ligase IV.
Greco GE; Matsumoto Y; Brooks RC; Lu Z; Lieber MR; Tomkinson AE
DNA Repair (Amst); 2016 Jul; 43():18-23. PubMed ID: 27235626
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
Zhao Y; Thomas HD; Batey MA; Cowell IG; Richardson CJ; Griffin RJ; Calvert AH; Newell DR; Smith GC; Curtin NJ
Cancer Res; 2006 May; 66(10):5354-62. PubMed ID: 16707462
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of novel SCR7-based small-molecule inhibitor of DNA end-joining, SCR130 and its relevance in cancer therapeutics.
Ray U; Raul SK; Gopinatha VK; Ghosh D; Rangappa KS; Mantelingu K; Raghavan SC
Mol Carcinog; 2020 Jun; 59(6):618-628. PubMed ID: 32189406
[TBL] [Abstract][Full Text] [Related]
5. Autocyclized and oxidized forms of SCR7 induce cancer cell death by inhibiting nonhomologous DNA end joining in a Ligase IV dependent manner.
Vartak SV; Swarup HA; Gopalakrishnan V; Gopinatha VK; Ropars V; Nambiar M; John F; Kothanahally SKS; Kumari R; Kumari N; Ray U; Radha G; Dinesh D; Pandey M; Ananda H; Karki SS; Srivastava M; Charbonnier JB; Choudhary B; Mantelingu K; Raghavan SC
FEBS J; 2018 Nov; 285(21):3959-3976. PubMed ID: 30230716
[TBL] [Abstract][Full Text] [Related]
6. SCR7, a potent cancer therapeutic agent and a biochemical inhibitor of nonhomologous DNA end-joining.
Manjunath M; Choudhary B; Raghavan SC
Cancer Rep (Hoboken); 2021 Jun; 4(3):e1341. PubMed ID: 33496064
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of DNA-PK potentiates the synergistic effect of NK314 and etoposide combination on human glioblastoma cells.
Kopa P; Macieja A; Gulbas I; Pastwa E; Poplawski T
Mol Biol Rep; 2020 Jan; 47(1):67-76. PubMed ID: 31583565
[TBL] [Abstract][Full Text] [Related]
8. SCR7, an inhibitor of NHEJ can sensitize tumor cells to ionization radiation.
Gopalakrishnan V; Sharma S; Ray U; Manjunath M; Lakshmanan D; Vartak SV; Gopinatha VK; Srivastava M; Kempegowda M; Choudhary B; Raghavan SC
Mol Carcinog; 2021 Sep; 60(9):627-643. PubMed ID: 34192388
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effect of three different topoisomerase II inhibitors combined with cisplatin in human glioblastoma cells sensitized with double strand break repair inhibitors.
Macieja A; Kopa P; Galita G; Pastwa E; Majsterek I; Poplawski T
Mol Biol Rep; 2019 Aug; 46(4):3625-3636. PubMed ID: 31020489
[TBL] [Abstract][Full Text] [Related]
10. Wortmannin potentiates the combined effect of etoposide and cisplatin in human glioma cells.
Pastwa E; Poplawski T; Lewandowska U; Somiari SB; Blasiak J; Somiari RI
Int J Biochem Cell Biol; 2014 Aug; 53():423-31. PubMed ID: 24953561
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of DNA-PK by knockdown DNA-PKcs or NU7441 impairs non-homologous end-joining of radiation-induced double strand break repair.
Dong J; Ren Y; Zhang T; Wang Z; Ling CC; Li GC; He F; Wang C; Wen B
Oncol Rep; 2018 Mar; 39(3):912-920. PubMed ID: 29344644
[TBL] [Abstract][Full Text] [Related]
12. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839).
Friedmann B; Caplin M; Hartley JA; Hochhauser D
Clin Cancer Res; 2004 Oct; 10(19):6476-86. PubMed ID: 15475435
[TBL] [Abstract][Full Text] [Related]
13. Pluronic copolymer encapsulated SCR7 as a potential anticancer agent.
John F; George J; Srivastava M; Hassan PA; Aswal VK; Karki SS; Raghavan SC
Faraday Discuss; 2015; 177():155-61. PubMed ID: 25608025
[TBL] [Abstract][Full Text] [Related]
14. Depletion of tyrosyl DNA phosphodiesterase 2 activity enhances etoposide-mediated double-strand break formation and cell killing.
Kont YS; Dutta A; Mallisetty A; Mathew J; Minas T; Kraus C; Dhopeshwarkar P; Kallakury B; Mitra S; Üren A; Adhikari S
DNA Repair (Amst); 2016 Jul; 43():38-47. PubMed ID: 27235629
[TBL] [Abstract][Full Text] [Related]
15. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression.
Srivastava M; Nambiar M; Sharma S; Karki SS; Goldsmith G; Hegde M; Kumar S; Pandey M; Singh RK; Ray P; Natarajan R; Kelkar M; De A; Choudhary B; Raghavan SC
Cell; 2012 Dec; 151(7):1474-87. PubMed ID: 23260137
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of nonhomologous end joining to increase the specificity of CRISPR/Cas9 genome editing.
Vartak SV; Raghavan SC
FEBS J; 2015 Nov; 282(22):4289-94. PubMed ID: 26290158
[TBL] [Abstract][Full Text] [Related]
17. Nontoxic concentration of DNA-PK inhibitor NU7441 radio-sensitizes lung tumor cells with little effect on double strand break repair.
Sunada S; Kanai H; Lee Y; Yasuda T; Hirakawa H; Liu C; Fujimori A; Uesaka M; Okayasu R
Cancer Sci; 2016 Sep; 107(9):1250-5. PubMed ID: 27341700
[TBL] [Abstract][Full Text] [Related]
18. Sensitizing thermochemotherapy with a PARP1-inhibitor.
Oei AL; Vriend LE; van Leeuwen CM; Rodermond HM; Ten Cate R; Westermann AM; Stalpers LJ; Crezee J; Kanaar R; Kok HP; Krawczyk PM; Franken NA
Oncotarget; 2017 Mar; 8(10):16303-16312. PubMed ID: 27557507
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks.
Dong J; Zhang T; Ren Y; Wang Z; Ling CC; He F; Li GC; Wang C; Wen B
Oncotarget; 2017 Apr; 8(14):22662-22673. PubMed ID: 28186989
[TBL] [Abstract][Full Text] [Related]
20. DNA Double-Strand Break Repair Inhibitors: YU238259, A12B4C3 and DDRI-18 Overcome the Cisplatin Resistance in Human Ovarian Cancer Cells, but Not under Hypoxia Conditions.
Macieja A; Gulbas I; Popławski T
Curr Issues Mol Biol; 2023 Sep; 45(10):7915-7932. PubMed ID: 37886943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
